Alar Pharmaceuticals is entering the emerging pet pharmaceutical market with ALA-1000, a drug for chronic pain in pets. The company recently completed field trials involving 12 dogs in Taiwan. Following data analysis, Alar plans to submit a drug approval application by the end of the year, while simultaneously negotiating overseas licensing agreements. The company also announced an upcoming extraordinary shareholders’ meeting to amend portions of its Articles of Incorporation, mainly to add animal drug sales as a business item to support future regulatory filings.
According to market research, nearly 40% of dogs are diagnosed with osteoarthritis (OA), and 40% of cats show signs of OA-related pain. In the U.S., an estimated 65 million dogs and over 32 million cats suffer from cancer-related pain. The global veterinary pain management market reached US$2.58 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 6.8% from 2025 to 2030.
For proof-of-concept studies targeting OA pain in dogs, Alar conducted field trials with 12 dogs, which have recently completed enrollment. Once the final subject’s data is received, analysis will commence, with the goal of submitting a drug approval application to Taiwan’s Council of Agriculture by year-end. Based on feedback from veterinarians, cat owners show even greater willingness to invest in treatment, and Alar plans to advance development for feline OA therapies.
In terms of market competition, existing products include Librela, a monoclonal antibody administered monthly, which achieved over US$4 million in sales in its first quarter. However, emerging safety concerns regarding musculoskeletal injury have prompted more cautious clinical use. Alar highlighted that ALA-1000, formulated as an improved opioid-based drug, demonstrates over 60% efficacy—surpassing the sub-50% performance of monoclonal antibodies. The drug is easy to administer via low-dose insulin-style injections, is well-tolerated by dogs with minimal side effects, can be combined with NSAIDs, and remains stable at room temperature. With the global demand for pet medications rapidly increasing, Alar expects ALA-1000 to become a new growth driver.
Traditional human pain medications used in pets often pose risks such as kidney burden, creating strong demand among veterinarians for safe and effective long-acting formulations. Alar emphasized that ALA-1000’s clinical data and ease of use have already earned strong recognition from veterinarians. Following regulatory approval, the company plans to first launch the product for dogs, then gradually expand to cats and other indications, aiming to capitalize on the rising global pet healthcare expenditure. Overseas licensing discussions are ongoing in parallel.
Alar Pharmaceuticals recently announced that an extraordinary shareholders’ meeting will be held on November 11 to discuss amendments to its Articles of Incorporation. The revisions are primarily to add animal drug sales as a business item, reflecting the faster-than-expected completion of the ALA-1000 field trials and supporting subsequent drug approval applications.
Resource: 昱展攻寵物疼痛藥市場，拚年底在台送藥證申請，海外授權同步進行
